Tonix Pharmaceuticals announced significant preclinical results for its immuno-oncology candidate TNX-1700 at the American Association for Cancer Research (AACR) 2025 Annual Meeting. The research revealed promising findings in gastric cancer treatment, highlighting the potential of a novel approach to cancer immunotherapy.
The preclinical study demonstrated that a fusion protein version of TFF2 could substantially reduce immunosuppressive neutrophils while simultaneously enhancing anti-tumor immune responses. Notably, these effects were most pronounced when the fusion protein was combined with anti-PD1 therapy, suggesting a potential synergistic treatment strategy.
The research represents a critical advancement in understanding tumor microenvironment manipulation. By targeting and reducing immunosuppressive cells, TNX-1700 could potentially improve the effectiveness of existing cancer treatments, particularly in gastric and colon cancers.
Currently licensed from Columbia University, TNX-1700 is part of Tonix's strategic approach to developing innovative cancer treatments. The findings provide early evidence of the candidate's potential to address current limitations in cancer immunotherapy, where existing treatments may be hindered by the complex tumor microenvironment.
While preclinical data are preliminary, the results suggest TNX-1700 could represent a promising direction for future cancer treatment strategies, potentially offering new hope for patients with challenging forms of gastric and colon cancers.
